TORONTO, ON / ACCESSWIRE / December 3, 2019 / Soricimed, a privately-held, science-based company focused on the development and commercialization of drug candidates for the treatment of solid-tumor cancers, environmentally responsible pesticides and novel active skin-care products, announced today that management will present an update on the Company's business at the first annual BioTuesdays Pre-JPM Virtual Conference on Tuesday, December 10, 2019 at 1:30 p.m. Eastern Time.
The live and archived presentation webcast can be accessed here.
About Soricimed Biopharma Inc.: Soricimed is a privately-held, science-based company focused on the development and commercialization of applications originally derived from its unique and proprietary family of peptides found in the paralytic venom of the northern short-tailed shrew. Product development is ongoing for three distinct verticals: as targeted drug candidates for the treatment of solid-tumor cancers; as an environmentally responsible pesticide for the agriculture and aquaculture sectors; and as novel active ingredients in skin-care products for the cosmetic industry. For more information visit www.soricimed.com.
Media Relations:
Julie A. Fotheringham
Partner, HAGEMAN Communications
Julie.fotheringham@hageman.ca
416.951.7988
Investor Relations:
Stephen Kilmer
President, Kilmer Lucas Inc.
stephen@kilmerlucas.com
646.274.3580
SOURCE: Soricimed Biopharma
View source version on accesswire.com:
https://www.accesswire.com/568702/Soricimed-to-Present-at-the-First-Annual-BioTuesdays-Pre-JPM-Virtual-Conference
